Real‐world experience with lecanemab therapy for Alzheimer's disease in the Intermountain West
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2026-01 · 18 (1)
DOI: 10.1002/dad2.70251 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, online erschienen am 18.01.2026. Verfasst von Bethany C Curd und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology University of Utah Salt Lake City Utah USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Lecanemab is a monoclonal antibody targeting amyloid plaques that has been approved for the treatment of early symptomatic Alzheimer's disease. Here, we report on the clinical history and outcomes of the first 70 patients at the University of Utah to receive amyloid‐removal therapy. METHODS This is a retrospective analysis of patients treated with lecanemab over a 26‐month period. We extracted patient data from charts and analyzed demographics, health history, and clinical details with outcomes on lecanemab treatment. RESULTS In total, we observed 14 cases (20%) of amyloid‐related imaging abnormalities (ARIAs), which was significantly associated with apolipoprotein E ε4 homozygosity. Zero cases of ARIAs were symptomatic, and there was no association between distance from clinic and adverse effects. DISCUSSION Our study examined the safety and tolerability of centrally managed lecanemab administration across a widely distributed region and suggests that use of distributed infusion sites increases access to disease‐modifying treatment without significant increase in risk. Highlights Lecanemab therapy can be safely administered to patients across a broadly distributed area through a single clinical center. In our first 70 treated patients, 14 developed amyloid‐related imaging abnormalities (ARIAs)—a rate of 20%, which is consistent with clinical trials of lecanemab. No patients experienced symptomatic ARIAs. ARIA incidence was significantly associated with apolipoprotein E genotype, but not other demographic factors, comorbid conditions, or baseline clinical details.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology University of Utah Salt Lake City Utah USA.
- Division of Geriatrics, Department of Internal Medicine University of Utah Salt Lake City Utah USA.
- Department of Radiology and Imaging Sciences University of Utah Salt Lake City Utah USA.
- Division of Hematology & Hematologic Malignancies, Department of Internal Medicine University of Utah Salt Lake City Utah USA.
ORCID-Profile: Nicholas A Frost
Zitieren
APA
Curd, B. C., Zubrick, C., Brown, C. J. C., Sorweid, M. K., Dehoney, S. B., Anzai, Y., Minoshima, S., Parks, A. L., & Frost, N. A. (2026). Real‐world experience with lecanemab therapy for Alzheimer's disease in the Intermountain West. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 18(1). https://doi.org/10.1002/dad2.70251
Vancouver
Curd BC, Zubrick C, Brown CJC, Sorweid MK, Dehoney SB, Anzai Y, et al. Real‐world experience with lecanemab therapy for Alzheimer's disease in the Intermountain West. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2026;18(1). doi:10.1002/dad2.70251
BibTeX
@article{Curd2026,
author = {Curd, Bethany C and Zubrick, Camilla and Brown, Christine J Cliatt and Sorweid, Michelle Keown and Dehoney, Sarah B and Anzai, Yoshimi and Minoshima, Satoshi and Parks, Anna L and Frost, Nicholas A},
title = {Real‐world experience with lecanemab therapy for Alzheimer's disease in the Intermountain West},
journal = {Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring},
year = {2026},
volume = {18},
number = {1},
doi = {10.1002/dad2.70251}
}
EUVIMED